Eisai Co Ltd (ESALF) 59.2500 $ESALF Global

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Eisai Co Ltd (ESALF) 59.2500 $ESALF

Global Mitogen-Activated Protein Kinase 8 Pipeline Report 2016 - Celgene Corporation, Eisai Co., Ltd. & OPKO Health, Inc. - Research and Markets
BusinessWire - Fri Aug 12, 9:59AM CDT
Research and Markets has announced the addition of the "Mitogen-Activated Protein Kinase 8 (c-jun-N-Terminal Kinase 1 or JNK-46 or Stress-Activated Protein Kinase JNK1 or EC 2.7.11.24) - Pipeline Review, H1 2016" report to their offering.
OPK: 9.83 (-0.03), CELGZ: 1.11 (-0.12)

Eisai Presents Results of Additional Analysis of Phase III Study of Anticancer Agent Halaven at 14th JSMO Annual Meeting Plenary Session
JCN Newswire - Mon Aug 01, 6:46AM CDT
Eisai Co., Ltd. announced today that the results of an additional analysis of a Phase III clinical study (Study 309) of its in-house discovered and developed anticancer agent Halaven in patients with locally advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). The study was presented at a plenary session of the 14th Japanese Society of Medical Oncology (JSMO) Annual Meeting held in Kobe from July 28 to 30, 2016. The presenter was Dr. Patrick Schoffski of University Hospitals Leuven, Belgium.

Eisai and Mamorio to Jointly Develop "Me-MAMORIO" Tracking Tool to Support People With Dementia Going Out
JCN Newswire - Mon Aug 01, 6:05AM CDT
Eisai Co., Ltd. and MAMORIO, Inc. announced today that they have entered into an agreement to collaborate on the development of the Me-MAMORIO(1) tracking tool to support people with dementia going out. The two companies will conduct a demonstration experiment aiming for implementation as well as development of Me-MAMORIO under cooperation with various stakeholders including the government, healthcare professionals and care workers.

Eisai Enters into a Collaboration Agreement to Co-Promote LENVIMA® (Lenvatinib) in Combination with Everolimus in the U.S.
PR Newswire - Thu Jun 02, 3:15PM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Novartis Pharmaceuticals Corporation, an affiliate of Basel, Switzerland-based Novartis AG, have entered into an agreement to collaborate on commercial and medical affairs activities for LENVIMA® capsules in combination with everolimus in the United States for the treatment of patients with advanced renal cell carcinoma (aRCC), who were previously treated with an anti-angiogenic therapy.
NVS: 81.34 (-0.60)

Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate)
JCN Newswire - Wed May 25, 6:38AM CDT


Maria Garrigan appointed Vice President, Global Regulatory Strategy, Oncology Business Group at Eisai Inc.
PR Newswire - Tue May 24, 7:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Maria Garrigan, as Vice President, Global Regulatory Strategy for the Oncology Business Group (OBG).

Eisai to Present New Research on Oncology Products and Pipeline at 52nd Asco Annual Meeting
JCN Newswire - Mon May 23, 8:36PM CDT
TOKYO, May 24, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that a series of abstracts highlighting new study results on Halaven (eribulin mesylate; halichondrin class microtubule dynamics inhibitor, "eribulin" and Lenvima (lenvatinib mesylate; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, "lenvatinib" will be presented during the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 3 to 7, 2016.

U.S. FDA Approves Additional Indication for Eisai's Anticancer Agent Lenvima in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma
JCN Newswire - Sun May 15, 10:44PM CDT
TOKYO, May 16, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. This is the only combination regimen to significantly prolong progression-free survival (PFS) when compared with a standard of care in patients with advanced renal cell carcinoma following prior anti-angiogenic therapy. Lenvima was designated as a Breakthrough Therapy by the FDA and also received a Priority Review, with approval obtained approximately six months after application submission.

Dr. Avinash Desai appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group at Eisai Inc.
PR Newswire - Wed Apr 20, 7:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Avinash Desai, MD, as Vice President, Americas Oncology Medical Affairs for the Oncology Business Group (OBG).

Beyhan Zaim appointed Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group at Eisai Inc.
PR Newswire - Mon Apr 11, 7:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Beyhan Zaim as Vice President Commercial Development & Alzheimer's Disease Global Lead, Neurology Business Group.

Paul Hawthorne appointed Senior Vice President, U.S. Commercial, Neurology Business Group at Eisai Inc.
PR Newswire - Wed Apr 06, 7:00AM CDT
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Paul Hawthorne to the position of Senior Vice President, U.S. Commercial, Neurology Business Group. In this role, Mr. Hawthorne will be responsible for leading the U.S. Neurology Sales and Marketing teams in bringing Eisai's neurology portfolio of products to patients.

Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma
JCN Newswire - Mon Apr 04, 8:11PM CDT
TOKYO, Apr 5, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Halaven (eribulin mesylate) for treatment of adult patients with unresectable liposarcomas who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. Halaven is the first and only single agent to demonstrate an overall survival (OS) benefit in a Phase III trial in patients with advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). Following approval for use in the treatment of metastatic breast cancer in the EU, this marks the second indication for which Halaven has received a positive CHMP opinion based on a statistically significant extension of OS.

Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories
JCN Newswire - Thu Mar 31, 3:34AM CDT
TOKYO, Mar 31, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. (Dr. Reddy's).
RDY: 45.08 (-0.54)

Eisai's Notice Concerning Shelf Registration for Issuance of Stock Options
JCN Newswire - Wed Mar 30, 10:27PM CDT
TOKYO, Mar 30, 2016 - (JCN Newswire) - Eisai Co., Ltd. ("the Company" today filed a shelf registration statement with the Kanto Local Finance Bureau for issuance of stock options in accordance with the Company's "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy".This submission corresponds to the expiration of the previous shelf registration (period from April 7, 2014 to April 6, 2016) filed on March 28, 2014.

Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd.
JCN Newswire - Wed Mar 30, 9:35PM CDT


Eisai's Notification Regarding Revision of Consolidated Financial Results Forecasts (IFRS) for the Fiscal Year Ending March 31, 2016
JCN Newswire - Wed Mar 30, 9:35PM CDT
TOKYO, Mar 30, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on February 2, 2016, as follows:

Global Drug Maker Eisai Signs Three-Year Contract Extension For CSC's Total Regulatory Solution (TRS) as-a-Service
BusinessWire - Wed Mar 30, 9:00AM CDT
CSC (NYSE: CSC), a global leader in next-generation IT services and solutions, announced today that Eisai Inc. has signed a three-year contract extension for CSC's Total Regulatory Solutions (TRS) as-a-Service. The agreement extends the ongoing life sciences software and cloud-hosting services CSC provides to Tokyo-based Eisai Co., Ltd.'s U.S. pharmaceutical subsidiary until December 2019.
CSC: 46.04 (+0.28)

Eisai's In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) Approved in Japan
JCN Newswire - Mon Mar 28, 10:07PM CDT


Eisai Withdraws New Drugs Application for Mecobalamin Ultra-High Dose Preparation as Treatment for Amyotrophic Lateral Sclerosis
JCN Newswire - Tue Mar 22, 2:17AM CDT
TOKYO, Mar 22, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has withdrawn its new drug application for ultra-high dose Mecobalamin development code: E0302) as a treatment for amyotrophic lateral sclerosis (ALS) in Japan.

Helsinn and Eisai Announce Revised U.S. Collaboration for CINV Franchise
PR Newswire - Fri Mar 18, 6:55AM CDT
Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, and Eisai Inc., the U.S. pharmaceutical subsidiary of the research-based human healthcare company Eisai Co., Ltd , announced today a revised agreement for their chemotherapy-induced nausea and vomiting (CINV) franchise.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 89

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 24

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 183

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 155

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 106

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Mars Moves on Cash Tender Offers for Seniors' Notes

Updated Category News Views 52

A Strategic Financial Maneuver or a Casual Gambit? Okay, what’s Mars up to now, you ask? Here we go with this. The behemoth behind some of your favorite snacks and pet indulgences is making waves—not with candy, but with cash. Mars, Incorporated is rolling out tender offers to buy back a substantial chunk of its Senior Notes for $2 billion in cold, hard cash. When a...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Welcomes New Leaders to Enhance Transactions Team

Updated Category News Views 162

FTI Consulting Expands Expertise in Transactions Practice FTI Consulting, Inc. has recently announced the addition of two seasoned M&A professionals to its Transactions practice within the Corporate Finance & Restructuring segment. This strategic move aims to enhance their offerings and support clients in managing complex transactions. Introduction of M&A Experts The...

Continue Reading
BetaNXT Recognized as Leader in Wealth Management Innovation

Updated Category News Views 309

BetaNXT Earns Recognition as a Trendsetter in Wealth Management BetaNXT has captured attention in the financial technology landscape, particularly with its groundbreaking DataXChange platform. This innovative solution is designed to enhance modernization and innovation in wealth management, fostering business growth through a connected data ecosystem. Finalist in...

Continue Reading
OysterLink Sees Record Interest in Hospitality Job Searches

Updated Category News Views 124

Surging Demand for Restaurant and Hospitality Positions New analysis indicates that interest in restaurant and hospitality jobs has surged, reaching the highest level seen in five years. This summer's data from OysterLink's platform, combined with nationwide Google Trends, showcases a remarkable uptick in searches and applications, highlighting a strong rebound in the...

Continue Reading
Innovative Lithium Battery Solutions Enhanced by ITU and Huawei

Updated Category News Views 315

Joint Innovations in Lithium Battery Technology At the prestigious Global Digital Power Summit, a collaboration between the International Telecommunication Union (ITU) and Huawei brought significant attention to lithium battery applications for telecom sites. With industry leaders and experts congregating, the dialogue centered around technological advancements aimed at...

Continue Reading
Licel vTEE Continues to Lead in EMVCo TEE Success

Updated Category News Views 130

Licel vTEE Achieves EMVCo Approval Again The groundbreaking virtual trusted execution environment, Licel vTEE, stands out as the only SBMP TEE to receive evaluation and approval from EMVCo. This marks another milestone in the continued recognition of Licel's innovative technology. Unprecedented Recognition for Android Platform Licel's vTEE has received re-evaluation and...

Continue Reading